{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-043141","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.383058+00:00","generated_at":"2026-05-30T07:21:57.522900+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Cocrystal Pharma highlights in vitro activity of CC-42344 against avian H5N1, Phase 2a data expected by end of 2024","bullets":["CC-42344 showed in vitro activity against avian influenza A (H5N1) PB2 protein; high-resolution crystal structure confirmed binding.","Phase 2a human challenge study for seasonal influenza A topline safety/tolerability results expected by end of 2024.","Phase 1 study of pan-viral candidate CDI-988 for noroviruses and coronaviruses; topline data expected late 2024 or early 2025.","No approved vaccine or antiviral for norovirus; estimated 685M cases and 200K deaths annually worldwide (CDC).","Preparations underway for US IND application for late-stage study of CC-42344."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-043141","json":"https://secwatch.observer/filing/0001493152-24-043141.json","markdown":"https://secwatch.observer/filing/0001493152-24-043141.md","text":"https://secwatch.observer/filing/0001493152-24-043141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224043141/0001493152-24-043141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224043141/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:21:57.522900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}